The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference
1Department of Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: hasheme@bcm.edu.
2The Coalition for Global Hepatitis Elimination, The Task Force for Global Health, Decatur, Georgia.
3Baylor University Medical Center, Dallas, Texas.
4Department of Medicine, University of Texas Southwestern Medical Center Dallas, Texas.
5Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
6UnitedHealthcare Community Plan of Texas, Sugar Land, Texas.
7Department of Medicine, Keck School of Medicine of USC, Los Angeles, California.
8Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
9Department of Medicine, Baylor College of Medicine, Houston, Texas.
10Department of Medicine, Montefiore Medical Center, Bronx, New York.
Abstract
Background & aims: Texas has the highest age-adjusted incidence rate of hepatocellular carcinoma (HCC) in the United States.1 The Cancer Prevention and Research Institute of Texas has funded the Texas Collaborative Center for Hepatocellular Cancer (TeCH) to facilitate HCC research, education, and advocacy activities with the overall goal of reducing HCC mortality in Texas through coordination, collaboration, and advocacy.2 METHODS: On September 17, 2022, TeCH co-sponsored a multi-stakeholder conference on HCC with the Baker Institute Center for Health and Biosciences. This conference was attended by HCC researchers, policy makers, payers, members from pharmaceutical industry and patient advocacy groups in and outside of Texas. This report summarizes the results of the conference.
Results: The goal of this meeting was to identify different strategies for preventing HCC and evaluate their readiness for implementation.
Conclusions: We call for a statewide (1) viral hepatitis elimination program; (2) program to increase nonalcoholic steatohepatitis and obesity awareness; (3) research program to develop health care models that integrate alcohol associated liver disease treatment and treatment for alcohol use disorder; and (4) demonstration projects to evaluate the effectiveness of identifying and linking patient with advanced fibrosis and cirrhosis to clinical care.